Brokers Issue Forecasts for Electromed FY2025 Earnings

Electromed, Inc. (NYSE:ELMD) – Equities researchers at Roth Capital issued their FY2025 earnings estimates for Electromed in a research note issued to investors on Monday, July 21st. Roth Capital analyst K. Bauser expects that the company will earn $0.81 per share for the year. Roth Capital currently has a “Strong-Buy” rating on the stock. Roth Capital also issued estimates for Electromed’s Q4 2025 earnings at $0.22 EPS, Q1 2026 earnings at $0.22 EPS, Q2 2026 earnings at $0.31 EPS, Q3 2026 earnings at $0.21 EPS, Q4 2026 earnings at $0.26 EPS, FY2026 earnings at $1.00 EPS and FY2027 earnings at $1.15 EPS.

Several other analysts have also issued reports on the company. Wall Street Zen lowered Electromed from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 8th. B. Riley raised Electromed to a “strong-buy” rating in a research note on Thursday, May 15th.

Electromed Trading Down 2.2%

ELMD stock opened at $18.64 on Thursday. The company’s 50 day moving average is $20.27 and its 200 day moving average is $24.58. The stock has a market cap of $156.32 million, a price-to-earnings ratio of 24.85 and a beta of 0.41. Electromed has a 1-year low of $13.74 and a 1-year high of $35.56.

Institutional Trading of Electromed

Institutional investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. purchased a new stake in shares of Electromed during the fourth quarter valued at approximately $37,000. State of Wyoming purchased a new stake in shares of Electromed during the first quarter valued at approximately $48,000. Quantbot Technologies LP purchased a new stake in shares of Electromed during the fourth quarter valued at approximately $99,000. Bank of America Corp DE boosted its stake in shares of Electromed by 179.2% during the fourth quarter. Bank of America Corp DE now owns 4,004 shares of the company’s stock valued at $118,000 after purchasing an additional 2,570 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Electromed during the fourth quarter valued at approximately $119,000. Hedge funds and other institutional investors own 40.82% of the company’s stock.

About Electromed

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.